The significant preliminary result was growth of a Staphylococcus species (unspecified) in one blood culture bottle. We commenced cefuroxime 750 mg tid parenterally. We repeated the full blood count on days one and three of cefuroxime therapy and noted the platelet count to have fallen to 92 x 109/1. We considered this to be due to presumed infection or a side-effect of medication. On day five of cefuroxime therapy we received the final microbiological report on the blood culture identifying the organism as Staphylococcus epidermidis, a contaminant skin commensal.
Summary
We present the case of a 77-year-old man who became thrombocytopenic whilst treated parenterally with cefuroxime in the absence of proven infection and recovered when the cefuroxime was discontinued.
Keywords: cefuroxime, thrombocytopenia Since 1966 there have been a number of case reports suggesting a link between cephalosporin therapy and blood dyscrasias, especially thrombocytopenia.1 In each case the causal link remains unproven because of the presence of confounding variables and the ethical position that precludes re-exposure of the sensitive individual to confirm the cause and effect. An immunological mechanism has been described in cefotetan-induced thrombocytopenia where potent IgG-cefotetan-dependent antiplatelet antibodies were detected in the patient's serum.2 An animal model in the dog has also been described.3
Case report
A 77-year-old man known to suffer from mild Alzheimer's disease and recurrent depressive disorder was admitted with a 10-day history of increasing anxiety and agitation and worsening depression. Examination revealed marked psychomotor agitation, perseverations and verbal stereotypies. His cognitive functioning had deteriorated. He appeared physically ill with a fluctuating conscious level, tachycardia, tachypnoea and profuse sweating. He remained apyrexial.
We diagnosed acute confusional state (delirium ICD 10) superimposed on mild dementia precipitating a relapse of his depressive disorder. We started haloperidol 5 mg bid on admission. Investigations included full blood count, erythrocyte sedimentation rate, midstream urine and urinary electrolytes, liver function tests, calcium, glucose, thyroid function tests, VDRTIPA, three sets of blood cultures, malarial parasites, a chest X-ray and an electrocardiogram.
The significant preliminary result was growth of a Staphylococcus species (unspecified) in one blood culture bottle. We commenced cefuroxime 750 mg tid parenterally. We repeated the full blood count on days one and three of cefuroxime therapy and noted the platelet count to have fallen to 92 x 109/1. We considered this to be due to presumed infection or a side-effect of medication. On day five of cefuroxime therapy we received the final microbiological report on the blood culture identifying the organism as Staphylococcus epidermidis, a contaminant skin commensal.
We stopped cefuroxime and repeated the full blood count days later, finding that the platelet count had risen to 164 x 109/l. Nine days later it was 325 x 109/1. The diagnosis was now a severe depressive episode. A course of electroconvulsive therapy was started on the day after 
